Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. has demonstrated a strong growth trajectory, with an expected substantial increase in its legacy Performance Suite Medical Expense Ratio (MER) and an anticipated sequential EBITDA improvement of $10-15 million in the upcoming quarters. The company's ability to cross-sell services and expand its risk-based product offerings to large clients positions it well for outsized growth, particularly with a target of $150 million in EBITDA by the end of 2026. Furthermore, Evolent Health is on track for significant top-line growth and improved margins, which underscores its leadership in specialty-focused, value-based care services.

Bears say

Evolent Health Inc.'s outlook appears negative due to projected revenue declines, specifically with a forecasted loss of approximately $100 million stemming from the legacy Performance Suite, leading to an anticipated revenue of about $850 million for that segment in 2026. Additionally, the company's guidance indicates only $20 million in EBITDA for the first quarter, with expectations for flat sequential performance in Q2, suggesting limited growth potential in the near term. Furthermore, downward adjustments to earnings per share estimates for fiscal years 2026 and 2027, along with a significant reduction in the price target, reflect a lack of confidence in the company's ability to stabilize its financial performance amidst ongoing market challenges.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.